{
    "2019-04-29": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Better Big Pharma Stock: AbbVie vs. AstraZeneca",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "AstraZeneca",
                        "pharma"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-02-22",
                "original_text": "AbbVie Raises EPS Guidance for Fiscal 2019",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "EPS",
                        "guidance",
                        "fiscal 2019"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-02-22",
                "original_text": "AbbVie Reiterates Revenue Guidance for Fiscal 2019",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "revenue",
                        "guidance",
                        "fiscal 2019"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-04-25",
                "original_text": "What Analysts Are Recommending for AbbVie after Q1 Results",
                "features": {
                    "keywords": [
                        "Analysts",
                        "AbbVie",
                        "Q1 results"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-05-10",
                "original_text": "3 Reasons Why Growth Investors Shouldn't Overlook AbbVie (ABBV)",
                "features": {
                    "keywords": [
                        "Growth investors",
                        "AbbVie",
                        "overlook"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-06-15",
                "original_text": "AbbVie (ABBV) Upgraded to Buy: Here's Why",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "upgraded",
                        "buy"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-07-20",
                "original_text": "Why AbbVie (ABBV) is a Great Dividend Stock Right Now",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "dividend",
                        "stock"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-08-10",
                "original_text": "A Look at Cosentyx, Novartisâ€™s Fast-Growing Immunology Drug",
                "features": {
                    "keywords": [
                        "Cosentyx",
                        "Novartis",
                        "immunology",
                        "drug"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-09-25",
                "original_text": "Here are the biggest analyst calls of the day: Target, Disney, CVS, American Airlines, & more",
                "features": {
                    "keywords": [
                        "analyst calls",
                        "Target",
                        "Disney",
                        "CVS",
                        "American Airlines"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "retail",
                        "entertainment",
                        "healthcare",
                        "airlines"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "mixed",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "mixed"
                }
            }
        ]
    ]
}